189 related articles for article (PubMed ID: 9733667)
21. Bioavailability of orally administered mesna.
Burkert H; Lücker PW; Wetzelsberger N; Breuel HP
Arzneimittelforschung; 1984; 34(11):1597-600. PubMed ID: 6441581
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
[TBL] [Abstract][Full Text] [Related]
23. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
van Besien K; Rodriguez A; Tomany S; Younes A; Donato M; Sarris A; Giralt S; Mehra R; Andersson B; Gajewski J; Champlin R; Cabanillas F
Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
[TBL] [Abstract][Full Text] [Related]
25. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
Sutton G; Brunetto VL; Kilgore L; Soper JT; McGehee R; Olt G; Lentz SS; Sorosky J; Hsiu JG
Gynecol Oncol; 2000 Nov; 79(2):147-53. PubMed ID: 11063636
[TBL] [Abstract][Full Text] [Related]
26. Oral administration of mesna with ifosfamide.
Goren MP
Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
[TBL] [Abstract][Full Text] [Related]
27. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F
Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
[TBL] [Abstract][Full Text] [Related]
28. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.
Barişta I; Tekuzman G; Yalçin S; Güllü I; Güler N; Ozişik Y; Kars A; Celik I; Türker A; Altundağ K; Zengin N; Uner A; Baltali E; Firat D
J Surg Oncol; 2000 Jan; 73(1):12-6. PubMed ID: 10649272
[TBL] [Abstract][Full Text] [Related]
29. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma.
McNiel NO; Morgan LR
Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):490-3. PubMed ID: 7298241
[TBL] [Abstract][Full Text] [Related]
30. High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease.
Bonfante V; Viviani S; Devizzi L; Di Russo A; Di Nicola M; Magni M; Matteucci P; Grisanti S; Valagussa P; Bonadonna G; Gianni AM
Eur J Haematol Suppl; 2001 Jul; 64():51-5. PubMed ID: 11486403
[TBL] [Abstract][Full Text] [Related]
31. Anticipated administration of GM-CSF in the treatment of non small cell lung cancer.
Erkisi M; Erkurt E; Zeren H; Tunali C; Kocabas A; Burgut R
J Exp Clin Cancer Res; 2001 Sep; 20(3):345-9. PubMed ID: 11718213
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma.
Kim DW; Jo YH; Kim JH; Wu HG; Rhee CS; Lee CH; Kim TY; Heo DS; Bang YJ; Kim NK
Cancer; 2004 Nov; 101(10):2257-60. PubMed ID: 15484215
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
34. Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
Liu YL; Tsai SH; Chang FW; Yu MH
Taiwan J Obstet Gynecol; 2010 Mar; 49(1):77-80. PubMed ID: 20466298
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
[TBL] [Abstract][Full Text] [Related]
36. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide.
Goren MP; Anthony LB; Hande KR; Johnson DH; Brade WP; Frazier MW; Bush DA; Li JT
J Clin Oncol; 1998 Feb; 16(2):616-21. PubMed ID: 9469350
[TBL] [Abstract][Full Text] [Related]
38. Role of thiamine in managing ifosfamide-induced encephalopathy.
Hamadani M; Awan F
J Oncol Pharm Pract; 2006 Dec; 12(4):237-9. PubMed ID: 17156595
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
[TBL] [Abstract][Full Text] [Related]
40. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
Crotzer DR; Wolf JK; Gano JB; Gershenson DM; Levenback C
Gynecol Oncol; 2007 May; 105(2):399-403. PubMed ID: 17292457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]